MorphoSys AG sell DirectorDealer_Intensive
Summary
This prediction ended on 12.12.16 with a price of €44.00. The SELL prediction by DirectorDealer_Intensive for MorphoSys AG closed nearly unchanged from the start price. DirectorDealer_Intensive has 50% into this predictionMorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| MorphoSys AG | 0.147% | 0.147% | 191.506% | -3.890% |
| iShares Core DAX® | -1.347% | 3.576% | 14.229% | 18.356% |
| iShares Nasdaq 100 | 1.169% | 7.020% | 35.388% | 58.850% |
| iShares Nikkei 225® | -0.327% | -0.673% | 8.618% | 6.718% |
| iShares S&P 500 | 0.510% | 4.445% | 28.019% | 49.406% |
Comments by DirectorDealer_Intensive for this prediction
In the thread Morphosys AG diskutieren
Director Dealing: Verkauf
Director Dealing / Insider Verkauf von Hostein, Jens (Geschäftsführendes Organ)
- Handelstag: 07.06.16
- Volumen: 470028 €
- Meldender: Hostein, Jens
Wir werten alle Insider Käufe aus. Gemeinsam mit der Universität Innsbruck wurde eine Handelsstrategie auf Basis des Intensive Tradings entwickelt. Mehr Informationen findest du im Profil von DirectorDealer_Intensive.